The integrin αvβ6: A novel target for CAR T-cell immunotherapy?

Biochemical Society Transactions

Volumn 44, Issue 2, 2016, Pages 349-355

  Whilding, Lynsey M ^a   Vallath, Sabari ^b   Maher, John ^a,c,d  

^a GUY S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BARNET HOSPITAL   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cancer; Chimeric antigen receptor; Immunotherapy; Integrins; T cells; v 6

Indexed keywords

ALPHAVBETA6 INTEGRIN; ALPHAVBETA6 INTEGRIN BLOCKING ANTIBODY; BLOCKING ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; INTEGRIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; T LYMPHOCYTE; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PHYSIOLOGY; PROGNOSIS;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; INTEGRINS; NEOPLASMS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85009810534     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150249     Document Type: Article

References (55)

1. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M. et al. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25
2. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N. et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528
3. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F. et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517
4. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M. et al. (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549
5. Kakarla, S. and Gottschalk, S. (2014) CAR T cells for solid tumors: armed and ready to go? Cancer J. 20, 151-155
6. Whilding, L.M. and Maher, J. (2015) CAR T-cell immunotherapy: The path from the by-road to the freeway? Mol. Oncol. 9, 1994-2018
7. Ahmed, N., Salsman, V.S., Yvon, E., Louis, C.U., Perlaky, L., Wels, W.S., Dishop, M.K., Kleinerman, E.E., Pule, M., Rooney, C.M. et al. (2009) Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779-1787
8. Maude, S.L., Teachey, D.T., Porter, D.L. and Grupp, S.A. (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017-4023
9. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A. and Mackall, C.L. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195
10. Maude, S.L., Barrett, D., Teachey, D.T. and Grupp, S.A. (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119-122
11. Maher, J. (2014) Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr. Gene Ther. 14, 35-43
12. Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R. and Gratama, J.W. (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904-912
13. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851
14. Heslop, H.E. (2010) Safer CARS. Mol. Ther. 18, 661-662
15. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A. et al. (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688-1696
16. de Melker, A.A. and Sonnenberg, A. (1999) Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events. BioEssays 21, 499-509
17. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687
18. Breuss, J.M., Gallo, J., DeLisser, H.M., Klimanskaya, I.V., Folkesson, H.G., Pittet, J.F., Nishimura, S.L., Aldape, K., Landers, D.V., Carpenter, W. et al. (1995) Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108 (Pt 6), 2241-2251
19. Huang, X.Z., Wu, J.F., Cass, D., Erle, D.J., Corry, D., Young, S.G., Farese, Jr, R.V. and Sheppard, D. (1996) Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J. Cell Biol. 133, 921-928
20. Sugimoto, K., Kudo, M., Sundaram, A., Ren, X., Huang, K., Bernstein, X., Wang, Y., Raymond, W.W., Erle, D.J., Abrink, M. et al. (2012) The alphavbeta6 integrin modulates airway hyperresponsiveness in mice by regulating intraepithelial mast cells. J. Clin. Invest. 122, 748-758
21. Yu, Y., Chen, S., Lu, G.F., Wu, Y., Mo, L., Liu, Z.Q., Zheng, P.Y., Liu, Z. and Yang, P.C. (2014) Alphavbeta6 is required in maintaining the intestinal epithelial barrier function. Cell Biol. Int. 38, 777-781
22. Jackson, T., Clark, S., Berryman, S., Burman, A., Cambier, S., Mu, D., Nishimura, S. and King, A.M. (2004) Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J. Virol. 78, 4533-4540
23. Munger, J.S., Huang, X., Kawakatsu, H., Griffiths, M.J., Dalton, S.L., Wu, J., Pittet, J.F., Kaminski, N., Garat, C., Matthay, M.A. et al. (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328
24. Agrez, M., Chen, A., Cone, R.I., Pytela, R. and Sheppard, D. (1994) The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J. Cell Biol. 127, 547-556
25. Van Aarsen, L.A., Leone, D.R., Ho, S., Dolinski, B.M., McCoon, P.E., LePage, D.J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C. et al. (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 68, 561-570
26. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N. and Settleman, J. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500
27. Thomas, G.J., Lewis, M.P., Whawell, S.A., Russell, A., Sheppard, D., Hart, I.R., Speight, P.M. and Marshall, J.F. (2001) Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J. Invest. Dermatol. 117, 67-73
28. Thomas, G.J., Poomsawat, S., Lewis, M.P., Hart, I.R., Speight, P.M. and Marshall, J.F. (2001) alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J. Invest. Dermatol. 116, 898-904
29. Moore, K.M., Thomas, G.J., Duffy, S.W., Warwick, J., Gabe, R., Chou, P., Ellis, I.O., Green, A.R., Haider, S., Brouilette, K. et al. (2014) Therapeutic targeting of integrin alphavbeta6 in breast cancer. J. Natl. Cancer Inst. 106
30. van Leeuwen, R.L., Yoshinaga, I.G., Akasaka, T., Dekker, S.K., Vermeer, B.J. and Byers, H.R. (1996) Attachment, spreading and migration of melanoma cells on vitronectin. The role of alpha V beta 3 and alpha V beta 5 integrins. Exp. Dermatol. 5, 308-315
31. Berry, M.G., Goode, A.W., Puddefoot, J.R., Vinson, G.P. and Carpenter, R. (2003) Integrin beta1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness. Breast Cancer 10, 214-219
32. Sheppard, D., Rozzo, C., Starr, L., Quaranta, V., Erle, D.J. and Pytela, R. (1990) Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction. J. Biol. Chem. 265, 11502-11507
33. Bates, R.C., Bellovin, D.I., Brown, C., Maynard, E., Wu, B., Kawakatsu, H., Sheppard, D., Oettgen, P. and Mercurio, A.M. (2005) Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115, 339-347
34. Elayadi, A.N., Samli, K.N., Prudkin, L., Liu, Y.H., Bian, A., Xie, X.J., Wistuba, I.I., Roth, J.A., McGuire, M.J. and Brown, K.C. (2007) A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67, 5889-5895
35. Ahmed, N., Riley, C., Rice, G.E., Quinn, M.A. and Baker, M.S. (2002) Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 50, 1371-1380
36. Hazelbag, S., Kenter, G.G., Gorter, A., Dreef, E.J., Koopman, L.A., Violette, S.M., Weinreb, P.H. and Fleuren, G.J. (2007) Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316-324
37. Sipos, B., Hahn, D., Carceller, A., Piulats, J., Hedderich, J., Kalthoff, H., Goodman, S.L., Kosmahl, M. and Kloppel, G. (2004) Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45, 226-236
38. Jones, J., Watt, F.M. and Speight, P.M. (1997) Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J. Oral Pathol. Med. 26, 63-68
39. Hamidi, S., Salo, T., Kainulainen, T., Epstein, J., Lerner, K. and Larjava, H. (2000) Expression of alpha(v)beta6 integrin in oral leukoplakia. Br. J. Cancer 82, 1433-1440
40. Impola, U., Uitto, V.J., Hietanen, J., Hakkinen, L., Zhang, L., Larjava, H., Isaka, K. and Saarialho-Kere, U. (2004) Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J. Pathol. 202, 14-22
41. Regezi, J.A., Ramos, D.M., Pytela, R., Dekker, N.P. and Jordan, R.C. (2002) Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol. 38, 332-336
42. Thomas, G.J., Lewis, M.P., Hart, I.R., Marshall, J.F. and Speight, P.M. (2001) AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer 92, 641-650
43. Morgan, M.R., Thomas, G.J., Russell, A., Hart, I.R. and Marshall, J.F. (2004) The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J. Biol. Chem. 279, 26533-26539
44. Allen, M.D., Thomas, G.J., Clark, S., Dawoud, M.M., Vallath, S., Payne, S.J., Gomm, J.J., Dreger, S.A., Dickinson, S., Edwards, D.R. et al. (2014) Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin. Cancer Res. 20, 344-357
45. Ahmed, N., Niu, J., Dorahy, D.J., Gu, X., Andrews, S., Meldrum, C.J., Scott, R.J., Baker, M.S., Macreadie, I.G. and Agrez, M.V. (2002) Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene 21, 1370-1380
46. Kawashima, A., Tsugawa, S., Boku, A., Kobayashi, M., Minamoto, T., Nakanishi, I. and Oda, Y. (2003) Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol. Res. Pract. 199, 57-64
47. Hausner, S.H., Abbey, C.K., Bold, R.J., Gagnon, M.K., Marik, J., Marshall, J.F., Stanecki, C.E. and Sutcliffe, J.L. (2009) Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res. 69, 5843-5850
48. Saha, A., Ellison, D., Thomas, G.J., Vallath, S., Mather, S.J., Hart, I.R. and Marshall, J.F. (2010) High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J. Pathol. 222, 52-63
49. Eberlein, C., Kendrew, J., McDaid, K., Alfred, A., Kang, J.S., Jacobs, V.N., Ross, S.J., Rooney, C., Smith, N.R., Rinkenberger, J. et al. (2013) A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 32, 4406-4416
50. Violette, S., Sheppard, D., Rosas, I.O., Arjomandi, M., Rice, T., Gilman, M., Kaminski, N., Prasse, A. and Maroni, B. (2012) Identification of biomarkers to monitor the activity of STX-100, a humanized anti-αvβ6 antibody, in a phase 2a trial in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 185, A2659
51. Pameijer, C.R., Navanjo, A., Meechoovet, B., Wagner, J.R., Aguilar, B., Wright, C.L., Chang, W.C., Brown, C.E. and Jensen, M.C. (2007) Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14, 91-97
52. Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953-962
53. Leibovich, B.C., Sheinin, Y., Lohse, C.M., Thompson, R.H., Cheville, J.C., Zavada, J. and Kwon, E.D. (2007) Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25, 4757-4764
54. Yang, G.Y., Xu, K.S., Pan, Z.Q., Zhang, Z.Y., Mi, Y.T., Wang, J.S., Chen, R. and Niu, J. (2008) Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 99, 879-887
55. Arihiro, K., Kaneko, M., Fujii, S., Inai, K. and Yokosaki, Y. (2000) Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7, 19-26